We’ve written about Denver-based BioIntellisense quite often in the last 12 months. Last January we wrote about the company’s FDA-cleared BioSticker wearable sensor that stores data for up to 30 days. We covered the BioButton follow-up product in May. The BioButton is a disposable medical-grade wearable capable of storing data up to 90 days. Then in late December 2020 we noted the BioButton won a CES 2021 Best of Innovation Award.

During CES 2021, Royal Philips shouted out its growing role in home healthcare. Philips mentioned several specific initiatives including its collaboration with BioIntelliSense to use the BioSticker for remote patient monitoring (RPM). Philips touted its focus on using RPM with the BioSticker for people living with chronic conditions such as diabetes and heart disease. Philips also stressed the use of remote biosensors when at-risk patients are discharged from the hospital and return to their homes.

The COVID-19 pandemic has fueled the development and acceptance of remote patient management platforms. While this is a shift in medical care that had already begun, the virus crisis has accelerated its adoption. Multi-sensors like the BioSticker and BioButton didn’t just fall out of the sky because of the pandemic, but they appeared in with nearly perfect timing to enable the clinical-grade data that enables RPM.